Shaanxi Kanghui Pharmaceutical Co Ltd
SSE:603139
Shaanxi Kanghui Pharmaceutical Co Ltd
SSE:603139
Price:
25.57
CNY
-4.8%
Market Closed
Market Cap:
¥2.6B
Relative Value
The Relative Value of one
Shaanxi Kanghui Pharmaceutical Co Ltd
stock under the Base Case scenario is
16.72
CNY.
Compared to the current market price of 25.57 CNY,
Shaanxi Kanghui Pharmaceutical Co Ltd
is
Overvalued by 35%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
16.72
CNY
Overvaluation 35%
Multiples Across Competitors
Competitors Multiples
Shaanxi Kanghui Pharmaceutical Co Ltd Competitors
Shaanxi Kanghui Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shaanxi Kanghui Pharmaceutical Co Ltd
SSE:603139
|
2.6B CNY | 5 | -13.9 | -19.9 | -19.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
963B USD | 14.8 | 46.7 | 31.4 | 33.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
599.3B USD | 6.4 | 22.4 | 15.5 | 19.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
289B CHF | 4.6 | 30.3 | 12.8 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.4B CHF | 5.6 | 22.7 | 14 | 18 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 30.7 | 17 | 23.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.9B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
